Critical concepts in adaptive clinical trials

Clinical Epidemiology

Volumn 10, Issue , 2018, Pages 343-351

  Park, Jay J H ^a   Thorlund, Kristian ^b,c   Mills, Edward J ^b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

Adaptive designs; Adaptive enrichment; Bayesian adaptive trials; Response adaptive randomization; Sample size reassessment; Seamless trials

Indexed keywords

ADAPTIVE CLINICAL TRIAL (TOPIC); ADAPTIVE ENRICHMENT DESIGN; BAYES THEOREM; COST EFFECTIVENESS ANALYSIS; HUMAN; PATIENT SAFETY; RANDOMIZATION; RESPONSE ADAPTIVE RANDOMIZATION; REVIEW; SAMPLE SIZE; SEAMLESS TRIAL DESIGN; STUDY DESIGN; SYSTEMATIC ERROR; TIME FACTOR;

EID: 85047749613     PISSN: None     EISSN: 11791349     Source Type: Journal    
DOI: 10.2147/CLEP.S156708     Document Type: Review

References (25)

1. Hatfield I, Allison A, Flight L, Julious SA, Dimairo M. Adaptive designs undertaken in clinical research: a review of registered clinical trials. Trials. 2016;17(1):150.
2. Mistry P, Dunn JA, Marshall A. A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines. BMC Med Res Methodol. 2017;17(1):108.
3. United States Food and Drug Administration. Adaptive Designs for Medical Device Clinical Studies Guidance for Industry and Food and Drug Administration Staff. United States Department of Health and Human Services; 2016.
4. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Reflection paper on methodological issues in confirmatory clinical trials with flexible design and analysis plan. European Medicines Agency; 2006.
5. Meurer WJ, Legocki L, Mawocha S, et al. Attitudes and opinions regarding confirmatory adaptive clinical trials: a mixed methods analysis from the Adaptive Designs Accelerating Promising Trials into Treatments (ADAPT-IT) project. Trials. 2016;17:373.
6. Bartlett RH, Roloff DW, Cornell RG, Andrews AF, Dillon PW, Zwisch-enberger JB. Extracorporeal circulation in neonatal respiratory failure: a prospective randomized study. Pediatrics. 1985;76(4):479–487.
7. Saville BR, Connor JT, Ayers GD, Alvarez J. The utility of Bayesian predictive probabilities for interim monitoring of clinical trials. Clin Trials. 2014;11(4):485–493.
8. Bauer P, Bretz F, Dragalin V, Konig F, Wassmer G. Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls. Stat Med. 2016;35(3):325–347.
9. Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo JM, Ford GA; ASTIN Study Investigators. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke. 2003;34(11):2543–2548.
10. Grieve AP, Krams M. ASTIN: a Bayesian adaptive dose-response trial in acute stroke. Clin Trials. 2005;2(4):340–351.
11. Bauer P, Koenig F. The reassessment of trial perspectives from interim data-a critical view. Stat Med. 2006;25(1):23–36.
12. Casali PG, Le Cesne A, Poveda Velasco A, et al. Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group intergroup randomized trial in collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. J Clin Oncol. 2015;33(36):4276–4283.
13. Bolstad WM, Curran JM. Introduction to Bayesian Statistics. John Wiley & Sons, Inc., Hoboken, New Jersey; 2016.
14. Cuffe RL, Lawrence D, Stone A, Vandemeulebroecke M. When is a seamless study desirable? Case studies from different pharmaceutical sponsors. Pharm Stat. 2014;13(4):229–237.
15. Joura EA, Giuliano AR, Iversen OE, et al; Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–723.
16. Chen YH, Gesser R, Luxembourg A. A seamless phase IIB/III adaptive outcome trial: design rationale and implementation challenges. Clin Trials. 2015;12(1):84–90.
17. Simon N, Simon R. Adaptive enrichment designs for clinical trials. Biostatistics. 2013;14(4):613–625.
18. Antoniou M, Jorgensen AL, Kolamunnage-Dona R. Biomarker-guided adaptive trial designs in Phase II and Phase III: a methodological review. PLoS One. 2016;11(2):e0149803.
19. Park JW, Liu MC, Yee D, et al. Adaptive randomization of neratinib in early breast cancer. N Engl J Med. 2016;375(1):11–22.
20. Rugo HS, Olopade OI, DeMichele A, et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med. 2016;375(1):23–34.
21. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011;1(1):44–53.
22. Rosenblum M, Hanley DF. Adaptive enrichment designs for stroke clinical trials. Stroke. 2017;48(7):2021–2025.
23. Morgan T, Zuccarello M, Narayan R, Keyl P, Lane K, Hanley D. Preliminary findings of the minimally-invasive surgery plus rtPA for intracerebral hemorrhage evacuation (MISTIE) clinical trial. Acta Neurochir Suppl. 2008;105:147–151.
24. Hanley DF, Thompson RE, Muschelli J, et al. Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial. Lancet Neurol. 2016;15(12):1228–1237.
25. Legocki LJ, Meurer WJ, Frederiksen S, et al. Clinical trialist perspectives on the ethics of adaptive clinical trials: a mixed-methods analysis. BMC Med Ethics. 2015;16:27.